Phase 3 N=357 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
N/A N=200 A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Phase 2 N=38 Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary: Percentage of Participants With Objective Response (OR) — 39.5 Percentage of participants
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 2 N=192 A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Squamous Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 3 N=1,093 First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=288 Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Phase 2 N=172 A Study in Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Phase 2 N=100 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
Phase 3 N=427 Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Squamous Cell Carcinoma, Non-Small-Cell Lung
Primary: Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance — 3.12; 2.60 months — p=0.3486
Phase 3 N=633 First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Phase 4 N=109 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Phase 2 N=54 A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=159 A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Phase 2 N=27 A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
Non-small Cell Lung Cancer Metastatic · Targetable Oncogenes (EGFR, ALK, ROS1)
Primary: 1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) — 19 percentage of participants
Phase 2 N=28 Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
Phase 3 N=795 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Carcinoma, Non-Small-Cell Lung
Primary: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 — 2.63; 1.94 Months — p=0.0103
Phase 2 N=25 Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Phase 2 N=63 Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants
Phase 2 N=24 Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 16.7; 8.3 Percentage of Participants
Phase 2 N=117 Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
Squamous Cell Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) — 14.5 Percentage of Participants
N/A N=1,864 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Recurrent Squamous Cell Lung Carcinoma · Stage IV Squamous Cell Lung Carcinoma AJCC v7
Primary: Screen Success Rate — 655 Participants
Phase 2 N=50 Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Phase 2 N=4 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants